• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The side chains of sterols are degraded by fermentation with microorganisms capable of doing so in an improved manner by employing in such fermentations sterol derivatives of the formula <IMAGE> wherein n is 1 or 2; R1 is H or lower alkyl, R2 is alkyl, whose chain optionally is interrupted by an oxygen atom, or when n is 2, also a hydrogen atom; and R3 is a sterol side chain.
    公开号:SU980628A3
    申请号:SU772502698
    申请日:1977-07-15
    公开日:1982-12-07
    发明作者:Вебер Альфред；Кеннеске Марио；Даль Хельмут
    申请人:Шеринг Аг (Фирма)；
    IPC主号:
    专利说明:

    (5) METHOD FOR OBTAINING DERIVATIVES. ANDROSTAN-17-SHE
    The invention relates to the production of new derivatives of androstan-G / -one of the general formula
    E20 (CHRi) nO
    to obtain new intermediate products of general formula (I).
    The purpose of the invention is to expand the arsenal of new derivatives of androstzyz-17on, which are intermediate products in the synthesis of pharmacologically active steroids.
    The goal is achieved by the fact that the derivative of Sterol is a common formula;
    where is a single or double bond;
    n 1 or 2;
    And, - hydrogen;
    Rn - lower alkyl or in the case when
    p 2, also hydrogen, which are novel intermediates for the synthesis of numerous pharmacologically active steroids. Using the well-known microbiological method for determining the 17-alkyl chain in 17-alkyl-substituted steroids using microorganisms of the form Mycobacterium fij allows
    CH,
    15
    "20 (CHR,) flO
    20
    where ii, Hj, Cl and p have the indicated values, and R is hydrogen, ethyl, or methyl, is fermented by a culture of the microorganism Mycobacterium spec NRRL3805, capable of cleaving the side chain from the esterin, followed by isolation of the target product. The process is carried out in such a solution. As a lower alcohol, monomethyl ether, glycopene, dimethylformamide or dimethyl sulfoxide, the target product has a high yield. . . Example 1 A. In a 750 ml Erlenmeyer flask, 200 ml of a sterile nutrient solution containing 1 yeast extract, 0.45 sodium hydrogen phosphate, 0, potassium dehydrogen phosphate and 0.2 Tagate (R) 02 are placed and the pH is adjusted to 6.7, produced inoculated with the decantate of the dry culture of Mycobacterium spec NRRl-8-3805 and stirred for 3 days at a rotation speed of 190 rpm. B. In a 50 L fermenter with 0 L of sterile nutrient solution containing 1.23% yeast extract (65%), 0.68% potassium dihydrogen phosphate and 0.2% Tagat (, 2) and adjusted to pH 6 , 0, 200 ml of the grown culture of Mycobacte rium spec and cultured at 30 ° C are incubated by blowing air (2) for 48 hours. C.400 g of cholesterol is dissolved in 6 l of formaldehyde dimethyl acetal, mixed at room temperature is mixed with kQQ g 200 g of phosphorus pentoxide is added in portions and in portions, after which the mass is stirred for 2 hours at room temperature. p is separated by filtration from insoluble components, which are then washed with formaldehyde dimethylacetal, after which the solvent is distilled off in vacuo. After adding sodium carbonate solution, the solid crude product is filtered, washed with water and after drying, 440 g of Cs-methoxymethoxy-5-cholesten are obtained. The compound recrystallized from acetone has a melting point of 79-BO ° C. 400 g of 3p-methoxymethoxy-5 cholesten obtained in the above images is emulsified with 120 g of Tegin 10 liters of completely demineralized water and 40 ml of 1N hydrochloric acid sodium oxide at 95 ° C for 30 minutes using a Dis-DR-3-6-6 reactor (manufactured by Junke and Kunkel, Germany). Then the emulsion is sterilized for 20 at 120 ° C. D. A 50 L fermenter will fill 40 liters of sterile nutrient solution containing 2.0% Cornsteep liguor, 0.3% diammonium hydrogen phosphate and 0.25% Tagat (02 and adjusted to pH 6.5, then inoculated with 2 l of Mycacterium spec, air is blown (0.5 is stirred (250 rpm) and incubated for 24 hours at 30 ° C. Then an emulsion of 3/3-methoxymethoxy-5-cholesten is added to the culture (obtained according to section C) after which fermentation is carried out for 120 h. After the fermentation is completed, the culture is extracted three times with chloride each time using 5 liters of the latter, the ethylene chloride extract is filtered and evaporated in vacuo.The resulting residue (15b g) is chromatographed on a column filled with silica gel, the product is recrystallized from ethyl acetate, to give 86 g of Cu3-methoxymethoxy-5 androsten-17-one with a melting point of 129/131132 ° C. Example 2. A. A 2 L Zrlenmeyer flask with 500 ml of sterile nutrient medium was grown under conditions described in Example 1A, Mycobacterium spec NRRL B-3805. B. Similarly to Example 1C, 10 g of sitosterol was reacted and 11 g of 24-ethyl-Zr-methoxymethoxy-5-cholesten was obtained. The compound recrystallized from acetone has an mp. 70-71 ° C. 10 g of the 24-ethyl-3-p-methoxymethoxy-5-cholesten obtained in this way are emulsified with 10 g of Tegin for 10 minutes and 300 ml of water at 95 ° C using Ultra-Turrax (Dzhanka and Kunkel, Germany). The emulsion is sterilized for 20 minutes at 120 ° C. C. In each of 20 Erlenmeyer flasks, each with 85 ml of sterile nutrient medium containing -2, 0% Cornsteep liquor, 0.3% diammonium hydrogen phosphate, 0.25% Tagat 0.2. and adjusted to pH 6.5, 5 ml of the grown Mycobacterium spec culture were added and stirred at 220 rpm for 24 hours at 30 ° C. Then, 14 ml of 24-ethyl-3 (5 methoxymethoxy-5-cholesten) suspension (which corresponds to 0.5 g of 24-ethyl-3 (α-methoxymethoxy-5-cholesten)) was added to each culture, and fermented for 120 hours. on a shaking device. After treatment carried out analogously to example 1D, 2.1 g of C / methoxymethoxy-5-androsten-17 is obtained with mp 130132 C. Example 3. A.In the conditions of example 1C, input 10.5 g of stigmaster and 10, 5 g of 2-ethyl-ZL-methoxymethoxy-5,22-cholestadiene are obtained during the reaction. The compound crystallized from acetone has t, pl. B. Under the conditions described In Example 2B, 10 g of 2A-ethyl-3-methoxymethoxy-5.22-cholestadiene is emulsified. Under the conditions described in Examples 2A and C, 85 ml of Mycobacterium spec NftRL B-3805 are produced and produced mixing with} k ml of suspension of 2-ethyl-3-methoxymethoxy-5,22-cholestadiene (which corresponds to 0.5 g of 2-ethyl-3 |)-methoxymethoxy-5,2-cholestadiene). After incubation for the next 120 At 30 ° C, the shaking apparatus is processed in accordance with Example 1D. 2.3 g of 3 (5-methoxymethoxy-5 androsten-1u-one St. Pl. 130-132 ° C are obtained. Example t. A. 20 g of cholesterol are dissolved in 300 ml of formaldehyde ethyl acetate / mixing at room temperature mixing with 30 g of kieselgur and (15 g portions) of phosphorus thioxide, the mass is stirred at room temperature for 2 ° C. The solution is separated by filtration from the undissolved fraction, washed with formaldehyde diethyl acetal; at 0 ° C. After adding the acidic carbon dioxide solution sodium is filtered off the crude product, which is washed with water, resulting in 22.6 g of ethoxymethoxy-5-cholestbna after drying.The compound recrystallized from ethyl ester of acetic acid has a melting point of 6 -66 ° C B. Similar to Example 2B, emulsified 10 g of Sp-ethoxymethoxy-5 cholesta.C. Under the conditions of examples 2A and C, 85 ml of Mycobacteri um spec NRRL B-3805 culture and mixing with 1 ml of CG suspension) -toxymethoxy-5-choleste 8 on (this corresponds to 0, 5 g of 3-ethoxymethoxy-5 cholesten). After incubation for the next 120 hours, the shaking unit is processed by analogy with Example 1D. The result is 1.5 g Sp-ethoxymethoxy-5-andro walls-17-she with so pl. 121-123C. EXAMPLE 5 A.38.67 g of cholesterol was dissolved in 250 ml of methylene chloride and 1–4.2 g of formaldehyde-bis-glycol acetal monomethyl ether and stirred with 60 g of kieselgur and 30 g of pentooxide while stirring at room temperature. phosphorus, after which the reaction mixture is stirred for 1 h at room temperature. The solution is separated by filtration from the insoluble fraction, washed with methylene chloride and then neutralized with a methanolic solution of potassium hydroxide. After distilling off the solvent in vacuo, the product is dissolved in methyl alcohol, filtered, and the substance is crystallized by slowly evaporating the solvent. As a result, 25 g of (2,5-dioxa-xyloxy) -5-cholane with m. Pl. t1-t2 C. B. Under the conditions described in Example 2B, emulsified with 10 g of 3 / i- (2,5-dioxahexyloxy) -5-cholesten. C. Under the conditions described in Examples 2A and C, 25 ml of Mycobacteriurn spec NRRL B-3805 are obtained and mixed with 14 ml of 3fb- (2,5-dioxahexyloxy) -5-cholesten suspension, which corresponds to 0.5 g 3 (2,5-dioxahexyloxy) -6-cholesten. After incubation for the next 120 hours at 30 ° C, the shaking apparatus is treated as in Example 1D. The result is 1.75 g Sp-(2,5 dioxahexyloxy) -5-androsten-17 it Art. square 65-67 ° C. Example 6 A. 12 g of cholesterol are suspended in 100 ml of acetaldehyde dimethyl acetal, mixed with 25 g of kieselgur and stirred with 12 g of phosphorus pentoxide with stirring at room temperature, and the reaction mixture is stirred at room temperature for 5 minutes. The solution is separated by filtration from the insoluble fraction, the latter is washed with methylene chloride and the solution is neutralized with a methanolic solution of sodium hydroxide. After distilling off the solvent in vacuo, the resulting crude product is recrystallized from acetone with the addition of activated charcoal. As a result, 10.2 g, 3 p (1-methoxyethoxy) -5-cholesten are obtained. square .
    B. In a similar manner to Example 2B, 10 g of (1-methoxyethoxy) -5-hblesten is emulsified.
    C. Under the conditions described in examples 2A (and C), receive
    85 ml culture of Mycobacterium spec NRRL 6-3805, and mixed with 1A ml of suspension 3 / S (1 methoxyethoxy 5-cholesten) (this corresponds to 0.5 g Sp (1-methoxyethoxy-5 cholesten). After incubation for the next 120 at 30 ° C, the shaking apparatus is processed by analogy with Example 1 E. The result is 1.89 g of 3 | b- (1-methoxy-ethoxy) -5-androsten-17-one with t, pl. 118 ° C.
    Example/.
    A. 19j33 g of cholesterol is mixed in 20 ml of methylene chloride with 23.6 ml of vinyl ethyl ether and 85 mg of para-toluenesulfonic acid (anhydrous) and the reaction mixture is stirred for 1.5 hours at room temperature. After neutralization with sodium carbonate, the solution is extracted with a solution of chloride sodium, drying with sodium sulfate, after which the solvent is distilled off in vacuo. The oily crude product is chromatographed on silica gel using a mixture of hexane and ethyl acetate as the eluent. The result is 18, g / (Tethoxyethoxy) -5-cholesten in the form of a colorless waxy substance.
    B. Under the conditions described in Example 2B, 10 g of (1-ethoxyethoxy) -5 cholesten is emulsified,
    Co. Under the conditions described in examples 2A. and C, 85 ml of Mycobacterium spec NRRL B-3805 culture are obtained and mixed with 14 ml of suspension 3f) (1-ethoxyethoxy) -5-cholesten, which corresponds to 0.5 g. 3 / L- (1-ethoxyethoxy) -5-cholesten, After this, incubate for a further 120 m on a shaking device at. United cultures
    It is extracted with ethylene chloride, the extract is evaporated in vacuo, the residue is mixed with 70 ml of methyl alcohol, 12 ml of water and 6 ml of a concentrated solution of NSB, after which the mixture is heated for 1 hour at reflux temperature. After cooling to the reaction product, it is precipitated by adding 100 ml of water and then filtered. After recrystallization from acetone, 0.62 g of $ -androsten-3 / 2hal-17-one with m.p. 138 / H8-149 ° C. PRI me R 8.
    A.38.7 g of cholesterol is dissolved in 500 ml of methylene chloride, and the pre-prepared solution is mixed with 25 ml of ethylene oxide and 0.5 ml of boron trifluoride etherate. The reaction mixture was incubated overnight at room temperature, then dried with sodium sulphate and extracted with water and the solvent was removed in vacuo. The crude product (50 g) is chromatographed.
    on silica gel using a mixture of hexane and ethyl OPO ester of acetic acid as an eluent. The result is 10 g of 3fb- (2-hydroxyethoxy) -5-cholesten, with so pl, 91-95 ° C.
    B. When the conditions described in examples 2A (and C) are met
    85 ml of Mycobacterium spec NRRL 8-3805 and mixed with 1 ml of 3 / 3- (2-hydroxyethoxy) -5-cholesten suspension, which corresponds to 0.5 g (2-hydroxy-ethoxy) -5-cholesten. After being cultivated for 120 hours, the shaking apparatus is processed by analogy with Example 1D. The result is 2.1 g of H / b (2-hydroxyethoxy) -5-androsten-17-one Art. square 173 / 175177С.
    Example 9
    A. According to Example 1C, 20 g of 5c-cholestan-3 / L ola are reacted with formaldehyde dimethyl acetal, resulting in a yield of
    21.5 g of 3 / L-methoxymeto C-5o-cholestane. The compound recrystallized from acetone has a melting point of -5-68 ° C.
    B. Under the conditions described in example 2B, emulsify
    10 g 3 / L-methoxymethoxy-5o / .- cholestane.
    权利要求:
    Claims (1)
    [1]
    C. Subject to the conditions described in Example 2A (and C), 85 ml of Mycobacterium spec NRRL 99 B-3805 are obtained and mixed with ml of 3/1 methoxymethoxy 5o cholestane (this corresponds to 0.5 g 3 / E-methoxymethoxy). 5 o-cholestane). After incubation for 120 hours, the shaking apparatus is treated according to Example 1D. The result of 2.05 g 3 / methoxymethoxy-5 androstane-17-she Art. square 97-98 C. The formula of the invention. 1. A method for producing adrostane-17 derivatives of the general formula E20 (CHRi) /, 0 where is a single or double bond; n - 1 or 2; R-, is hydrogen; 8 K "is the lowest alkyl or if it is also hydrogen, characterized in that the sterol derivative of the general formula is BaOCen where. , R, K2I l have the indicated values, and R hydrogen, methyl or ethyl, is fermented by a culture of the microorganism Mycobacterlurn spec NRRL 8-3805, capable of cleaving the side chain from sterol, followed by isolation of the target product. Sources of information taken into account in the examination 1, US Patent No., cl. 195.51, pub. 1972.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU980628A3|1982-12-07|Process for producing derivatives of androstane-17-one
    US4416985A|1983-11-22|Process for preparing 3β,7β-dihydroxy-Δ5 -steroids
    EP1534732B1|2006-09-13|5 androsten-3-ol steroid intermediates and processes for their preparation
    US4230625A|1980-10-28|Process for chenodeoxycholic acid and intermediates therefore
    EP0350488B1|1993-09-08|1,2-dehydrogenation of steroidal 21-esters witha. simplex
    US4301246A|1981-11-17|Process for chenodeoxycholic acid production
    SU697053A3|1979-11-05|Method of producing derivatives of 5-androstene-17-one
    SU876059A3|1981-10-23|Method of producing 11 beta-hydroxysteroids
    PL91090B1|1977-02-28|
    KR970005319B1|1997-04-15|Process for preparation of pregnenooxazolines
    DE2712861A1|1978-09-28|HYDROXYLATED 1 ALPHA, 2 ALPHA-METHYL STEROIDS
    US4603013A|1986-07-29|Estrane derivatives
    US4784953A|1988-11-15|Process and microorganism for degrading steroids
    US4592868A|1986-06-03|11-hydroxypregn-4-en-3-one-20-carbaldehyde and a method for its production
    RU2082762C1|1997-06-27|Process for preparing 17-oxosteroids
    US4212940A|1980-07-15|Process for the preparation of 21-hydroxy-20-methylpregnane derivatives
    US3198809A|1965-08-03|Microbiological reduction process and steroid products produced thereby
    US3939187A|1976-02-17|15α,-Sulfonyloxy-12β-hydroxypregnanes and process for the preparation thereof
    US5472854A|1995-12-05|Process for the production of 17-oxosteroids via the fermentative oxidation of 17β-hydroxysteroids by Mycobacterium
    US3577318A|1971-05-04|Process for making 6-hydroxy-3-keto delta**4-steroids of the pregnane and androstane series
    US5429934A|1995-07-04|Process for the production of 20-methyl-5,7-pregnadiene-3β,21-diol derivatives using mycobacterium
    US4419287A|1983-12-06|Stereocontrolled synthesis of steroidal side chains
    CS200520B2|1980-09-15|Process for preparing derivatives of androstan-17-one
    Petzoldt et al.1983|Process for preparing 3β, 7β-dihydroxy-Δ 5-steroids
    US4432905A|1984-02-21|Simplified process for the degradation of steroid-C-22-carboxylic acids
    同族专利:
    公开号 | 公开日
    FR2365588A1|1978-04-21|
    CH627190A5|1981-12-31|
    JPS5315493A|1978-02-13|
    SE440779B|1985-08-19|
    DD136141A5|1979-06-20|
    DK142372B|1980-10-20|
    HU182681B|1984-02-28|
    DK323677A|1978-01-17|
    IE45304L|1978-01-16|
    DE2632677C2|1988-06-16|
    CH629503A5|1982-04-30|
    IE45304B1|1982-07-28|
    IT1077339B|1985-05-04|
    JPS6117477B2|1986-05-07|
    FR2372174A1|1978-06-23|
    FR2365588B1|1982-06-25|
    NL7706638A|1978-01-18|
    GB1585786A|1981-03-11|
    CH629222A5|1982-04-15|
    BE856860A|1978-01-16|
    ATA504677A|1980-12-15|
    US4179336A|1979-12-18|
    YU164277A|1982-08-31|
    HU182790B|1984-03-28|
    FR2372175A1|1978-06-23|
    AT363196B|1981-07-10|
    HU182789B|1984-03-28|
    SE7708192L|1978-01-17|
    HU179344B|1982-10-28|
    DE2632677A1|1978-01-26|
    FR2372176A1|1978-06-23|
    DD136142A5|1979-06-20|
    DK142372C|1981-03-23|
    DD137235A5|1979-08-22|
    DD132439A5|1978-09-27|
    CS200517B2|1980-09-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3451892A|1965-10-19|1969-06-24|Schering Corp|Process for the preparation of steroidal compounds|
    NL6705450A|1965-10-22|1968-10-21|
    US3684657A|1970-05-11|1972-08-15|Searle & Co|Selective microbiological degradation of steroidal 17-alkyls|
    US3759791A|1970-12-10|1973-09-18|Searle & Co|Selective microbiological preparation of androst-4-ene-3,17-dione|
    US3738983A|1971-08-06|1973-06-12|Searle & Co|Process for the preparation of 3- propionic acid gamma-lactone|
    DE2534911C2|1975-08-01|1985-04-18|Schering AG, 1000 Berlin und 4709 Bergkamen|Process for the preparation of 5-androsten-17-one derivatives|JPS55148083A|1979-05-04|1980-11-18|Mitsubishi Chem Ind Ltd|Microorganism|
    JPS55150893A|1979-05-11|1980-11-25|Mitsubishi Chem Ind Ltd|Novel microorganism|
    JPH0120877B2|1980-06-17|1989-04-18|Mitsubishi Kasei Kk|
    US4444884A|1982-05-25|1984-04-24|Wisconsin Alumni Research Foundation|Process for preparing steroids|
    US4755463A|1982-05-25|1988-07-05|Wisconsin Alumni Research Foundation|Process for preparing steroids|
    JPH0512528Y2|1987-09-08|1993-03-31|
    EP0738703B1|1995-02-28|2002-05-22|Nippon Shokubai Co., Ltd.|Acrylic acid derivatives, method for preparing the acrylic acid derivatives, and acrylic acid polymers|
    US7887789B2|2003-05-23|2011-02-15|Nektar Therapeutics|Polymer derivatives having particular atom arrangements|
    JP5701308B2|2009-10-29|2015-04-15|インダストリー−アカデミック コーポレーション ファウンデーション，ヨンセイ ユニバーシティ|New vascular leak blocker|
    WO2012116290A2|2011-02-25|2012-08-30|Washington University|Neuroactive 17-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same|
    CN108976272B|2011-10-14|2021-05-25|萨奇治疗股份有限公司|3, 3-disubstituted 19-norpregnane compounds, compositions, and uses thereof|
    SI2935307T1|2012-12-18|2018-08-31|Washington University|Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment|
    WO2014127201A1|2013-02-15|2014-08-21|Washington University|Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for gaba type-a receptors|
    US9512170B2|2013-03-01|2016-12-06|Washington University|Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors|
    US9365502B2|2013-03-11|2016-06-14|Washington University|Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors|
    US9562026B2|2013-03-14|2017-02-07|Washington University|Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors|
    LT3498725T|2013-04-17|2021-09-27|Sage Therapeutics, Inc.|19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy|
    RU2019126333A|2013-04-17|2019-10-08|Сейдж Терапьютикс, Инк.|19-NOR NEUROACTIVE STEROIDS AND WAYS OF THEIR APPLICATION|
    WO2014169831A1|2013-04-17|2014-10-23|Sage Therapeutics, Inc.|19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof|
    WO2014169836A1|2013-04-17|2014-10-23|Sage Therapeutics, Inc.|19-nor neuroactive steroids and methods of use thereof|
    AU2014290400B2|2013-07-19|2019-12-05|Sage Therapeutics, Inc.|Neuroactive steroids, compositions, and uses thereof|
    WO2015195962A1|2014-06-18|2015-12-23|Sage Therapeutics, Inc.|Neuroactive steroids, compositions, and uses thereof|
    EP3753927A1|2014-10-16|2020-12-23|Sage Therapeutics, Inc.|Compositions and methods for treating cns disorders|
    RU2733756C2|2014-10-16|2020-10-06|Сейдж Терапьютикс, Инк.|Compositions and methods for treating cns disorders|
    PT3224269T|2014-11-27|2020-06-01|Sage Therapeutics Inc|Compositions and methods for treating cns disorders|
    RS61530B1|2015-01-26|2021-04-29|Sage Therapeutics Inc|Compositions and methods for treating cns disorders|
    EP3258939A4|2015-02-20|2018-08-29|Sage Therapeutics, Inc.|Neuroactive steroids, compositions, and uses thereof|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE2632677A|DE2632677C2|1976-07-16|1976-07-16|
    [返回顶部]